Mount Sinai West
New York, 10019, United States
NCT Number: NCT06559839
The VIP trial will assess the effectiveness, tolerability, and durability of effect of vestibulocortical stimulation (VCS) - a safe & cost-effective bedside technique - in treating pain, fatigue & related symptoms using validated patient-reported outcomes. Data from this trial will be used to guide optimized treatment protocols in future randomized controlled trials and help inform the implementation of VCS into standard clinical practice.
Looking for future studies?
Notify Me18 year–99 year
All sexes
Interventional
Not applicable
New York, 10019, United States
VCS is a form of non-invasive neuromodulation whereby cold water is irrigated into the external ear canal.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An individual with any of the following criteria will be excluded from participation in this study:
50cc of cold water (4℃) irrigated to the right external ear canal, at 1-2 cc/second, with the patient laying supine.
Other names: VCS
Time frame: Baseline and at 1 week after VCS
Change in diary pain scores on a 11 point numeric rating scale at 1 week after VCS as compared to baseline. Full scale from 0-10, with higher score indicating worse pain.
Time frame: Baseline and at 30 minutes, 24 hours, 2 weeks, and 4 weeks
Pain scores on an 11 point numeric rating scale at 30 minutes, 2 weeks, and 4 weeks after VCS as compared to baseline. Full scale from 0-10, with higher score indicating worse pain.
Time frame: 30 minutes, 24 hours, 1 week, 2 weeks, 4 weeks
Percentage of patients with change in pain assessed by NRS pain scores > equal to 30% and 50%. NRS full scale from 0-10, with higher score indicating worse pain.
Time frame: 24 hours
A 9-item instrument. Question 2 which is a diagram and question 7 which asks about medications, will be excluded. Total score from 0 to 10, with higher score indicating worse outcomes.
Time frame: 1 week, 2 weeks, 4 weeks
Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) measures seven domains: depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and the ability to participate in social roles and activities. Each domain has 4 questions ranked on a 5-point scale, and refer to the 7 previous days except physical function which has not time frame.
Scoring is standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points.
Higher scores indicate poorer health outcomes for anxiety, depression, fatigue, ability to participate in social roles and activities, and pain interference domains.
Lower scores reflect worse outcomes for physical function and sleep disturbances domains.
Time frame: at 30 minutes
Overall well-being scores on an 11 point numeric rating scale at 30 minutes. NRS full scale from 0-10, with higher score suggesting greater overall wellbeing.
Time frame: 24 hours post VCS
A seventeen question tolerability instrument developed specifically for caloric stimulation to assess tolerability by measuring the frequency and intensity of headaches, nausea, and vertigo. The tolerability scale does not have a total score just individual questions re headache nausea vertigo discomfort and grades intensities rated on a 0-10 scale, higher numbers reflecting higher severity of symptoms.
Time frame: 24 hours, 1 week, 2 week, 4 weeks
The Patient's Global Impression of Change (PGIC) will be used to assess pain. It will evaluate pain from no change (score 0-1), minimally improved (score 2-3), much improved (score 4-5), and very much improved (score 6-7). The patients will answer the following question: "Since beginning treatment at this program, how would you describe the change (if any) in activity limitations, symptoms, emotions, and overall quality of life related to your condition?". Full score from 0-7, with higher score indicating more improvement.
Time frame: 1 weeks, 2 weeks, 4 weeks
A 9-item scale, each item scored from 1 (strongly disagree) to 7 (strongly agree). Total scale from 9-63, with higher score indicating greater fatigue.
Time frame: 1 weeks, 2 weeks, 4 weeks
The Epworth Sleepiness Scale (ESS) is an 8-item measure that asks about the probability of dozing or sleeping during typical daytime activities. Scores correlate well with objective measures of speed of daytime sleep onset. The test is a list of eight situations in which the participate rates tendency to become sleepy on a scale of 0, no chance of dozing, to 3, high chance of dozing for each item. Total scale from 0 to 24, with higher score indicating severe excessive daytime sleepiness.
Time frame: 1 weeks, 2 weeks, 4 weeks
The COMPASS-31 (Composite Autonomic Symptom Score) is a comprehensive questionnaire used to evaluate symptoms of autonomic dysfunction in various body systems. It contains 31 questions across different 7 domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal (mixed upper and diarrhea), constipation, bladder, and pupillomotor function. Single cumulative weighted score designed to reflect global autonomic dysfunction. Score is 0-100, greater than or = to 20 suggests moderate to severe autonomic dysfunction
Icahn School of Medicine at Mount Sinai
Other
Vestibular Innovation in Pain: An Open Label Trial
Acronym: VIP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06828315
Brain Diseases, Central Nervous System Diseases
Muş, Turkey (Türkiye)
View Trial DetailsNCT05793736
Anxiety, Anxiety Disorders
Cagliari, Italy
View Trial DetailsNCT03194997
Behavior, Behavioral Symptoms
Florianópolis, Santa Catarina, Brazil
View Trial DetailsNCT00003685
Adenocarcinoma, Adenocarcinoma of Lung
Calgary, Alberta, Canada
View Trial Details